Franklin Street Advisors Inc. NC Purchases New Holdings in Fresenius Medical Care AG (NYSE:FMS)

Franklin Street Advisors Inc. NC acquired a new position in Fresenius Medical Care AG (NYSE:FMS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,896 shares of the company’s stock, valued at approximately $201,000.

Other large investors have also modified their holdings of the company. Allworth Financial LP grew its stake in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock worth $278,000 after purchasing an additional 624 shares during the period. MML Investors Services LLC raised its position in Fresenius Medical Care by 5.3% during the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after purchasing an additional 753 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after buying an additional 1,128 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after buying an additional 1,207 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Stock Up 0.7 %

Shares of NYSE FMS traded up $0.15 during trading hours on Friday, hitting $22.55. 69,266 shares of the stock were exchanged, compared to its average volume of 182,145. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $24.31. The firm has a fifty day moving average price of $22.45 and a 200-day moving average price of $20.74. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The company has a market cap of $13.23 billion, a PE ratio of 18.64, a PEG ratio of 0.95 and a beta of 0.92.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They issued a “strong-buy” rating for the company. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.